Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Invested Capital (2016 - 2025)

Sonoma Pharmaceuticals has reported Invested Capital over the past 15 years, most recently at $3.4 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 29.53% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, down 29.53%, while the annual FY2025 figure was $4.6 million, 28.31% down from the prior year.
  • Invested Capital for Q4 2025 was $3.4 million at Sonoma Pharmaceuticals, down from $3.8 million in the prior quarter.
  • Over five years, Invested Capital peaked at $11.7 million in Q3 2021 and troughed at $3.4 million in Q4 2025.
  • A 5-year average of $6.5 million and a median of $5.9 million in 2021 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: tumbled 54.09% in 2021 and later surged 67.76% in 2022.
  • Year by year, Invested Capital stood at $11.2 million in 2021, then tumbled by 50.23% to $5.6 million in 2022, then increased by 21.17% to $6.7 million in 2023, then fell by 27.7% to $4.9 million in 2024, then decreased by 29.53% to $3.4 million in 2025.
  • Business Quant data shows Invested Capital for SNOA at $3.4 million in Q4 2025, $3.8 million in Q3 2025, and $4.2 million in Q2 2025.